Table III.
Univariate and multivariate analyses of prognostic factors for EOC.
| Univariate analysisa | Multivariate analysisb | ||||
|---|---|---|---|---|---|
| Variables | n | Mean survival (months) | P-value | HR (95% CI) | P-value |
| FIGO stage | 4.922 (1.389–17.446) | 0.014c | |||
| I+II | 18 | 90.479±6.784 | 0.000d | ||
| III+IV | 42 | 36.968±4.901 | |||
| Histological grade | 1.556 (0.679–3.564) | 0.486 | |||
| I+II | 26 | 76.586±7.362 | 0.000d | ||
| III | 34 | 35.803±5.442 | |||
| CA125 (U/ml) | 0.528 (0.178–1.569) | 0.250 | |||
| >35 | 53 | 54.549±5.642 | 0.898 | ||
| ≤35 | 7 | 41.190±9.796 | |||
| Type | 2.014 (0.793–5.114) | 0.141 | |||
| I | 19 | 83.010±7.389 | 0.001d | ||
| II | 41 | 38.836±5.265 | |||
| FPR2 expression | 3.063 (1.193–7.864) | 0.020c | |||
| Low | 23 | 84.015±6.932 | 0.000d | ||
| High | 37 | 34.492±5.069 | |||
a
Log-rank test
b
Cox regression model.
c
P<0.05
d
P<0.01. EOC, epithelial ovarian cancer; HR, hazard ratio; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; FPR2, formyl peptide receptor 2.